| Glenda J Cook, MD | |
|
418 Cloverleaf Rd, Elizabethtown, PA 17022-9320 | |
| (717) 653-1467 | |
| (717) 653-1001 |
| Full Name | Glenda J Cook |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 33 Years |
| Location | 418 Cloverleaf Rd, Elizabethtown, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275503286 | NPI | - | NPPES |
| 110237772 | Other | PA | RAILROAD MEDICARE |
| 50000533 | Other | PA | CAPITAL BLUE CROSS |
| F87562 | Other | PA | HEALTH ASSURANCE |
| P004427 | Other | PA | GATEWAY HEALTH PLAN |
| 0014654500008 | Medicaid | PA | |
| 36826 S101 | Other | PA | GEISINGER HEALTH PLAN |
| 4505677 | Other | PA | AETNA NON-HMO |
| 143903 | Other | PA | HIGHMARK BLUE SHIELD |
| 513684 | Other | PA | AETNA HMIO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD053135L (Pennsylvania) | Primary |
| 207R00000X | Internal Medicine | MD053135L (Pennsylvania) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Masonic Village Home Health | Elizabethtown, PA | Home health agency |
| Penn Medicine Home Health Lancaster General Health | Lancaster, PA | Home health agency |
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Masonic Village At Elizabethtown | Elizabethtown, PA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Medical Group | 0941103683 | 463 |
News Archive
To help physicians decrease the number of deaths resulting from traumatic brain injuries, Chandan Reddy, associate professor in the Department of Computer Science and faculty at the Discovery Analytics Center, will use new machine learning techniques for computational models to predict short- and long-term outcomes, categorize traumatic brain injury patients, and provide interventions tailored to a specific patient and his or her injury.
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.
On behalf of the more than 5 million Americans living with Alzheimer's and their family members, the Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based on Phase 3 clinical trial results from the EMERGE and ENGAGE studies, and other related data, after finding a reduction of cognitive and functional decline in people taking the high dose.
Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.
› Verified 5 days ago
| Entity Name | Lancaster General Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952392383 PECOS PAC ID: 0941103683 Enrollment ID: O20040309000916 |
News Archive
To help physicians decrease the number of deaths resulting from traumatic brain injuries, Chandan Reddy, associate professor in the Department of Computer Science and faculty at the Discovery Analytics Center, will use new machine learning techniques for computational models to predict short- and long-term outcomes, categorize traumatic brain injury patients, and provide interventions tailored to a specific patient and his or her injury.
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.
On behalf of the more than 5 million Americans living with Alzheimer's and their family members, the Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based on Phase 3 clinical trial results from the EMERGE and ENGAGE studies, and other related data, after finding a reduction of cognitive and functional decline in people taking the high dose.
Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Glenda J Cook, MD 418 Cloverleaf Rd, Elizabethtown, PA 17022-9320 Ph: (717) 653-1467 | Glenda J Cook, MD 418 Cloverleaf Rd, Elizabethtown, PA 17022-9320 Ph: (717) 653-1467 |
News Archive
To help physicians decrease the number of deaths resulting from traumatic brain injuries, Chandan Reddy, associate professor in the Department of Computer Science and faculty at the Discovery Analytics Center, will use new machine learning techniques for computational models to predict short- and long-term outcomes, categorize traumatic brain injury patients, and provide interventions tailored to a specific patient and his or her injury.
Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.
On behalf of the more than 5 million Americans living with Alzheimer's and their family members, the Alzheimer's Association is encouraged to learn that Biogen will pursue regulatory approval from the FDA for the investigational drug aducanumab based on Phase 3 clinical trial results from the EMERGE and ENGAGE studies, and other related data, after finding a reduction of cognitive and functional decline in people taking the high dose.
Allos Therapeutics, Inc. announced today that the Agreement and Plan of Merger and Reorganization entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated.
› Verified 5 days ago
Neal S Harnly, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 418 Cloverleaf Rd, Elizabethtown, PA 17022 Phone: 717-653-1467 Fax: 717-653-1001 | |
Diana Tacelosky, M.D., PH.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Continental Dr, Elizabethtown, PA 17022 Phone: 717-531-5164 Fax: 717-531-0646 | |
Sarah Anne Lombel, PA-C Family Medicine Medicare: Medicare Enrolled Practice Location: 1 Continental Dr, Elizabethtown, PA 17022 Phone: 717-361-0666 | |
John J Mast, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 418 Cloverleaf Rd, Elizabethtown, PA 17022 Phone: 717-653-1467 Fax: 717-653-1001 | |
Scott C Conley, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 418 Cloverleaf Rd, Elizabethtown, PA 17022 Phone: 717-653-1467 Fax: 717-653-1001 | |
Christopher Michael Washington, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 432 Cloverleaf Rd, Elizabethtown, PA 17022 Phone: 717-544-6350 | |
Eric L Esch, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 418 Cloverleaf Rd, Elizabethtown, PA 17022 Phone: 717-653-1467 Fax: 717-653-1001 |